These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36130393)

  • 1. Seric IgG anti-SARS-CoV-2 pre- and post- Covid-19 pandemic from Mexican asymptomatic subjects.
    Aguirre-Cruz L; Guzmán-García M; Acosta-Castillo I; De la Cruz-Aguilera DL; Landero-Isidro I; Pérez-González JP; Chávez-Duarte J; Leyva-Rendón A
    Salud Publica Mex; 2022 Jun; 64(3, may-jun):249-258. PubMed ID: 36130393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
    Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
    BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of SARS-CoV-2 antibodies in blood donors during the third wave of infection in Campeche Mexico.
    Monteón V; Pérez FL; Hernández VP; Pacheco AO; Guzman PF; Torres GIG
    Transfus Apher Sci; 2022 Jun; 61(3):103374. PubMed ID: 35101375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG.
    Zarletti G; Tiberi M; De Molfetta V; Bossù M; Toppi E; Bossù P; Scapigliati G
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33171590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
    Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
    Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi.
    Hasan M; Moiz B; Qaiser S; Masood KI; Ghous Z; Hussain A; Ali N; Simas JP; Veldhoen M; Alves P; Abidi SH; Ghias K; Khan E; Hasan Z
    PLoS One; 2022; 17(8):e0271259. PubMed ID: 36001587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of SARS-CoV-2 infection and impact of the COVID-19 pandemic in avocado farmworkers from Mexico.
    Armendáriz-Arnez C; Tamayo-Ortiz M; Mora-Ardila F; Rodríguez-Barrena ME; Barros-Sierra D; Castillo F; Sánchez-Vargas A; Lopez-Carr D; Deardorff J; Eskenazi B; Mora AM
    Front Public Health; 2023; 11():1252530. PubMed ID: 38174080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-Cov-2 IgG antibodies in patients at a single center in Saudi Arabia.
    Mahallawi WH; Alsarani MA; Aljohani RH; Alluhaibi AA; Alamri TH; Ibrahim NA; Mahallawi KH; Khabourd OF
    Ann Saudi Med; 2022; 42(2):69-74. PubMed ID: 35380058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2: Insights into the epidemiology of the pandemic.
    Ali A; Waqar M; Akram A; Rafique S; Rehman G; Idrees M; Halim SA; Waqas M; Uddin J; Gojayev A; Khan A; Al-Harrasi A
    J Infect Public Health; 2023 Aug; 16(8):1256-1261. PubMed ID: 37300952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
    Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
    Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
    Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
    PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
    Dalakas MC; Bitzogli K; Alexopoulos H
    Front Immunol; 2021; 12():627285. PubMed ID: 33679770
    [No Abstract]   [Full Text] [Related]  

  • 15. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
    Rastawicki W; Płaza K
    Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland.
    Faller E; Wyse A; Barry R; Conlon K; Everard C; Finnegan P; Foran C; Herlihy E; Kerr G; Lapthorne S; McGreal-Bellone A; Morrissey E; O'Sullivan D; O'Sullivan G; Eustace JA; Spillane D; Dempsey C; Benson J; Prentice M; Gallagher J; MacSharry J; Fanning LJ; O'Riordan S; Horgan M; Sadlier C
    BMJ Open; 2021 Jun; 11(6):e051415. PubMed ID: 34103324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
    Levring MB; Holm DK; Nilsson AC; Bauer JM; Jensen IS; Davidsen JR; Rasmussen LD; Sprogøe U; Lillevang ST
    J Med Virol; 2022 Apr; 94(4):1711-1716. PubMed ID: 34845745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects.
    Achiron A; Gurevich M; Falb R; Dreyer-Alster S; Sonis P; Mandel M
    Clin Microbiol Infect; 2021 Sep; 27(9):1349.e1-1349.e6. PubMed ID: 33975009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of antibody responses after SARS-COV-2 infection in healthcare workers in the first wave of COVID-19 pandemic in Mexico City.
    Thompson-Bonilla MDR; León JA; Cárdenas-Turrent MB; Peña-Thompson A; Hanessian-De la Garza D; Zavala-Vega S; Xicohtencatl-Cortes J; Ochoa SA; Cruz-Córdova A; Arellano-Galindo J
    J Int Med Res; 2022 Jul; 50(7):3000605221099458. PubMed ID: 35879824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased SARS-CoV-2 seroprevalence in healthy blood donors after the second pandemic wave in South-Eastern Italy: evidence for asymptomatic young donors as potential virus spreaders.
    Antonucci F; Fiore JR; De Feo L; Granato T; Di Stefano M; Faleo G; Farhan AM; Margaglione M; Centra M; Santantonio TA
    Infect Dis (Lond); 2022 Apr; 54(4):241-246. PubMed ID: 34781812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.